skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Short-Term Effects of Ankaferd Hemostat for Renal Artery Embolization: An Experimental Study

Journal Article · · Cardiovascular and Interventional Radiology
 [1];  [2];  [1];  [3];  [4];  [5];  [6]; ;  [1]; ;  [5];  [7]
  1. Selcuk University, Department of Radiology, Meram School of Medicine (Turkey)
  2. Selcuk University, Division of Hematology, Department of Internal Medicine, Meram School of Medicine (Turkey)
  3. Afyon Kocatepe University, Department of General Surgery, Veterinary Faculty (Turkey)
  4. Selcuk University, Department of Pathology, Meram School of Medicine (Turkey)
  5. Selcuk University, Division of Nephrology, Department of Internal Medicine, Meram School of Medicine (Turkey)
  6. Selcuk University, Department of Radiology, Selcuklu School of Medicine (Turkey)
  7. Hacettepe University, Division of Hematology, Department of Internal Medicine, Faculty of Medicine (Turkey)

Renal artery embolization (RAE) is a minimally invasive therapeutic technique that is utilized in a number of disorders. Ankaferd is a novel hemostatic agent with a new mechanism of action independent of clotting factors. We used Ankaferd for RAE in a sheep model. Seven adult female sheep were included in the study. Selective renal arteriogram using 5-F diagnostic catheter was performed to make sure that each kidney was fed by a single renal artery and the animal had normal renal vasculature. Coaxial 2.7-F microcatheter was advanced to the distal main renal artery. Under fluoroscopic guidance, 2 mL of Ankaferd mixed with 2 mL of nonionic iodinated contrast agent was slowly injected. Fluoroscopy was used to observe the deceleration of flow and stagnation. Control renal angiograms were performed just after embolization. After the procedure, the animals were observed for 1 day and then sacrificed with intravenous sodium thiopental. The technical success was observed in seven of the seven animals.. After embolization procedure, none of the animals died or experienced a major systemic adverse event. On macroscopic examination of the embolized kidneys, thrombus at the level of main renal artery formed after Ankaferd embolization was more compact compared with the thrombi that was not Ankaferd-associated, which was observed elsewhere. Microscopically, majority of the renal tubular cells (80-90 %) were necrotic, and there was epithelial cell damage in a small portion of the cells (10-20 %). RAE was safe and effective in the short-term with Ankaferd in studied animals. Further studies should be conducted to better delineate the embolizing potential of this novel hemostatic agent.

OSTI ID:
22156379
Journal Information:
Cardiovascular and Interventional Radiology, Vol. 36, Issue 2; Other Information: Copyright (c) 2013 Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE); Article Copyright (c) 2012 Springer Science+Business Media, LLC and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE); Country of input: International Atomic Energy Agency (IAEA); ISSN 0174-1551
Country of Publication:
United States
Language:
English